Showing results (131-140 of 214) with videos related to
Sort By:
Pageof 22
Zeitschrift Fur Erkrankungen Der Atmungsorgane|January 1, 1990
[Comparative study of parenteral and oral immunization to influenza in a large clinical trial. 1. Results of clinico-epidemiologic studies]H Tischner, M Popp, H Herrmann, et al.Medical Microbiology and Immunology|November 30, 2002
Conceptional considerations for a German influenza pandemic preparedness planR Fock, H Bergmann, H Bussmann, et al.International Journal of Cancer|September 15, 1988
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinomaR Fåhraeus, H L Fu, I Ernberg, et al.Blood|August 8, 1998
Impaired activation of NFkappaB in T cells from a subset of renal cell carcinoma patients is mediated by inhibition of phosphorylation and degradation of the inhibitor, IkappaBalphaW Ling, P Rayman, R Uzzo, et al.Bone Marrow Transplantation|August 1, 1996
Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimenC F Waller, H Bertz, M K Wenger, et al.Bone Marrow Transplantation|March 7, 2003
Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrowL Garderet, M Labopin, N C Gorin, et al.Immunopharmacology and Immunotoxicology|January 27, 2006
Attempted passive prophylaxis with a monoclonal anti-Burkholderia pseudomallei exopolysaccharide antibody in a murine model of melioidosisChantal Bottex, Yves P Gauthier, Ralf M Hagen, et al.Bone Marrow Transplantation|September 20, 2016
Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMTS Eder, M Labopin, J Finke, et al.Cancer Research|October 15, 1994
T cells from renal cell carcinoma patients exhibit an abnormal pattern of kappa B-specific DNA-binding activity: a preliminary reportX Li, J Liu, J K Park, et al.Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|December 1, 1991
Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignanciesR M Bukowski, J S Sergi, G T Budd, et al.Pageof 22